

Ronald L. Wisor, Jr.

Partner

Washington, D.C.

Biography

For health care and life sciences companies uncompromising in their commitments to both business success and regulatory compliance, Ron Wisor is a valued strategic advisor, counselor, and advocate.

Whether it be a cutting-edge business plan, a key acquisition, or a high-stakes government investigation, Ron brings his deep understanding of health care regulation and his practical problem solving skills to bear in guiding health industry leaders through their most challenging legal compliance issues.

The primary focus of Ron's practice is health care fraud and abuse compliance, with an emphasis on helping clients navigate application of the anti-kickback, "Stark" self-referral, and false claims prohibitions in ways that allow them to engage in competitive business arrangements and promote greater access to their products and services.

A recognized leader among Washington, D.C. health care lawyers, Ron also regularly advises clients on coverage and reimbursement of new technologies, assists clients in addressing Medicare and Medicaid billing issues, and has vast experience in dealing with other complex regulatory issues in areas such as research compliance, genomics, personalized medicine, and digital health.



Phone

+1 202 637 5658

Fax

+1 202 637 5910

Email

ron.wisor@hoganlovells.com

Practices

Health Law

Pharmaceuticals and Biotechnology
Regulatory

Medical Device and Technology
Regulatory

Investigations, White Collar, and
Fraud

Industries

Life Sciences and Health Care

Education

Sports, Media & Entertainment

When the government comes calling through audits and investigations, Ron is a respected and effective advocate with the U.S. Department of Justice, the HHS Office of Inspector General, and the Centers for Medicare & Medicaid Services.

Nightingale's Healthcare News has named Ron as one of the "outstanding health care fraud and compliance lawyers" in the United States. His clients include multinational companies in the pharmaceutical, biotech, medical device, and clinical lab industries, as well as a number of leading health care providers and academic medical centers. Ron's broad client base and depth of experience allows him to benchmark clients' compliance safeguards against industry norms and evolving expectations of government regulators and enforcement authorities.

Representative experience

Advising a gene therapy manufacturer on market entry compliance issues, including the structuring of unique distribution service arrangements, patient access matters, and value-based payer agreements.

Advising a global biotech company on the structure of reimbursement support and nurse educator programs, and successfully defending those programs in a Department of Justice investigation.

In response to the COVID-19 pandemic, advising a global pharmaceutical company on its "telemedicine sprint" initiative to accelerate the company's connections with telemedicine service providers.

Awards and rankings

- Healthcare: Health Insurers, *Legal 500 US*, 2018
- Outstanding Physician Practice Lawyers, *Nightingale's Health Care News*, 2007
- Outstanding Healthcare Fraud and Compliance Lawyers, *Nightingale's Health Care News*, 2009

Areas of focus

False Claims Act and Qui Tam
Pharmaceuticals and Biotechnology
Medical Devices
Hospitals and Health Care Providers
Clinical Trials

Education and admissions

Education

J.D., Boston University School of Law, cum laude, 1993

B.A., Cornell University, 1986

Memberships

Chair, St. Columba's-Truesdell Educational Partnership (STEP)

Member, American Health Lawyers Association

Bar admissions and qualifications

Connecticut

District of Columbia

Latest thinking and events

- Hogan Lovells Publications
 - Life sciences and health care horizons 2021
- News
 - No Surprises Act prohibits balance billing, creates arbitration process for out-of-network providers
- News
 - HHS Regulatory Sprint takes final shape, Part 1: Substantial Stark Law regulatory revisions adopted
- News
 - HHS Regulatory Sprint takes final shape, Part 2: AKS, Stark regulatory revisions for value-based care
- News
 - Trump Administration revives rebate safe harbor rule in late effort to reform drug pricing
- News
 - OIG signals “significant concerns” with company-sponsored speaker programs